Ranbaxy Laboratories has received approval from the FDA to manufacture and market Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg. The Office of Generic Drugs, U.S. FDA, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as AstraZeneca’s drug Tenormin. Atenolol is indicated in the management of hypertension. It may be used alone or with other antihypertensive agents. Atenolol is also indicated for the long-term management of patients with a...